Uterine artery embolization versus myomectomy: impact on quality of life--results of the FUME (Fibroids of the Uterus: Myomectomy versus Embolization) Trial
Uterine artery embolization and myomectomy both significantly improved quality of life, with UAE offering shorter hospital stays and fewer complications but a higher reintervention rate.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
The FUME trial randomized women with symptomatic ultrasound-diagnosed uterine fibroids who wished to preserve their uterus to uterine artery embolization (UAE, n = 82) or myomectomy (n = 81) and compared quality of life at 1 year using a validated questionnaire, along with hospital stay, complications, and reintervention needs. Both groups had significant and equal improvements in quality of life by 1 year, while UAE required a shorter hospitalization (2 vs. 6 days) and had fewer major complications (2.9% vs. 8%, not statistically significant). By 2 years, reinterventions for inadequate symptom control were more frequent after UAE (14.0% vs. 2.7%), and among women who required hysterectomy, half had concomitant adenomyosis missed by ultrasound. This paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
Abstract
Full text
8,208 characters
· extracted from
oa-doi-fallback
· 5 sections
· click to expand
Abstract
Methods
Results
Conclusions
References
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Condition tags
MeSH descriptors
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (4)
- Long-Term Results of Uterine Artery Embolization for Symptomatic Adenomyosis 2006
- Uterine artery embolisation for symptomatic adenomyosis—Mid-term results 2008
- Midterm clinical and first reproductive results of a randomized controlled trial comparing uterine fibroid embolization and myomectomy. 2008
- Are the anticipated benefits of myomectomy achieved in women of reproductive age? A 5-year review of the results at a UK tertiary hospital 2004
References (29)
- Are the anticipated benefits of myomectomy achieved in women of reproductive age? A 5-year review of the results at a UK tertiary hospital via crossref
- Long-Term Results of Uterine Artery Embolization for Symptomatic Adenomyosis via crossref
- Midterm clinical and first reproductive results of a randomized controlled trial comparing uterine fibroid embolization and myomectomy. via crossref
- Uterine artery embolisation for symptomatic adenomyosis—Mid-term results via crossref
- doi:10.1016/j.ijgo.2006.07.009 via crossref
- doi:10.1016/s0015-0282(02)04538-7 via crossref
- doi:10.1097/01.rvi.0000092664.72261.f9 via crossref
- doi:10.1046/j.1471-0528.2002.01449.x via crossref
- doi:10.1097/01.rvi.0000231953.91787.af via crossref
- doi:10.1016/j.ajog.2007.02.029 via crossref
- doi:10.1056/nejmoa062003 via crossref
- doi:10.1016/j.ejogrb.2005.10.008 via crossref
- doi:10.1007/s002700010090 via crossref
- doi:10.1016/s0029-7844(01)01702-1 via crossref
- doi:10.1097/01.rvi.0000094620.61428.9c via crossref
- doi:10.1016/j.ajog.2010.01.049 via crossref
- doi:10.1016/j.jvir.2010.03.012 via crossref
- doi:10.1148/radiol.2303030111 via crossref
- doi:10.1007/s00270-007-9187-2 via crossref
- doi:10.1111/j.1471-0528.1991.tb13429.x via crossref
- doi:10.1097/01.aog.0000156298.74317.62 via crossref
- doi:10.1093/humrep/15.12.2663 via crossref
- doi:10.1002/14651858.cd003857.pub2 via crossref
- doi:10.1016/j.ogc.2005.12.008 via crossref
- doi:10.1016/j.bpobgyn.2008.01.012 via crossref
- doi:10.1016/j.fertnstert.2009.02.069 via crossref
- doi:10.1016/j.bpobgyn.2008.01.013 via crossref
- doi:10.1093/humrep/13.4.873 via crossref
- doi:10.1067/mob.2000.107730 via crossref
Source provenance
- crossref
- last seen: 2026-09-20T06:29:13.131846+00:00
- europepmc
- last seen: 2026-09-21T06:08:07.822426+00:00
- pubmed
- last seen: 2026-05-13T22:16:35.898691+00:00
- unpaywall
- last seen: 2026-09-24T06:17:16.569905+00:00
Courtesy of the U.S. National Library of Medicine